{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:25:30Z","timestamp":1787793930430,"version":"build-2784847793"},"reference-count":121,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Almirall S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The combined treatment with calcipotriol (Cal) and betamethasone dipropionate (BDP) has emerged as the leading anti-psoriatic topical treatment. Fixed-dose Cal\/BDP is available in different formulations, including ointment, gel, foam, and cream. This review examines the mechanism of action of Cal\/BDP underlying its therapeutic effect and compiles the evidence regarding its efficacy and safety compared to monotherapy with topical corticosteroids. The dual-action of Cal\/BDP targets the inflammatory pathways and abnormal keratinocyte proliferation, both of them fundamental mechanisms of psoriasis pathogenesis. A large number of randomized, double-blind studies support Cal\/BDP superiority over topical corticosteroids, demonstrating its broad efficacy across several degrees of psoriasis severity and its capability to provide early significant clinical improvements. This increased efficacy is achieved without negative effects on the safety profile, since the incidence of adverse effects reported with Cal\/BDP is usually similar to that of BDP and even lower than that of Cal alone. The combination therapy rapid onset of action, coupled with a simplified dosing regimen, has been identified as crucial for improving long-term adherence and patient outcomes. In conclusion, Cal\/BDP is confirmed as a versatile, effective, and convenient option for the patient in psoriasis management.<\/jats:p>","DOI":"10.3390\/jcm13154484","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T10:34:43Z","timestamp":1722422083000},"page":"4484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Calcipotriol\/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"first","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Gracia-Caza\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hjalmar","family":"Kurzen","sequence":"additional","affiliation":[{"name":"Haut- und Laserzentrum Freising, 85354 Freising, Germany"},{"name":"Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie am Biederstein, Technische Universit\u00e4t M\u00fcnchen, 80802 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Department, Almirall S.A., 08022 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s10067-016-3295-9","article-title":"Psoriatic Arthritis and Psoriasis: Differential Diagnosis","volume":"35","author":"Napolitano","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000232301","article-title":"Clinical Spectrum and Severity of Psoriasis","volume":"38","author":"Meier","year":"2009","journal-title":"Curr. Probl. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis Pathogenesis and the Development of Novel Targeted Immune Therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Su, R., Zhao, S., Zhang, J., Cao, M., and Peng, S. (2023). Metabolic Influences on T Cell in Psoriasis: A Literature Review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1279846"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"adv00030","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and Genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/1346-8138.13806","article-title":"Critical Role of Environmental Factors in the Pathogenesis of Psoriasis","volume":"44","author":"Zeng","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13555-021-00642-5","article-title":"Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology","volume":"12","author":"Papp","year":"2022","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1574886315666200128095958","article-title":"Treatment of Psoriasis: A Comprehensive Review of Entire Therapies","volume":"15","author":"Bakshi","year":"2020","journal-title":"Curr. Drug Saf."},{"key":"ref_10","first-page":"1209","article-title":"Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature","volume":"16","author":"Bagel","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lee, H.J., and Kim, M. (2023). Challenges and Future Trends in the Treatment of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713313"},{"key":"ref_12","first-page":"46","article-title":"The Rationale behind Topical Vitamin d Analogs in the Treatment of Psoriasis: Where Does Topical Calcitriol Fit In?","volume":"3","author":"Kim","year":"2010","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/10600280221105508","article-title":"Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis","volume":"57","author":"Taylor","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/jdv.18429","article-title":"European Guideline (EuroGuiDerm) on Atopic Eczema\u2014Part II: Non-Systemic Treatments and Treatment Recommendations for Special AE Patient Populations","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Topical Therapy and Alternative Medicine Modalities for Psoriasis Severity Measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/sji.12304","article-title":"The Vitamin D Analogue Calcipotriol Reduces the Frequency of CD8+ IL-17+ T Cells in Psoriasis Lesions","volume":"82","author":"Bonefeld","year":"2015","journal-title":"Scand. J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2017.07.033","article-title":"Inhibition of IL-17-Committed T Cells in a Murine Psoriasis Model by a Vitamin D Analogue","volume":"141","author":"Kusuba","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.06.003","article-title":"Distinctive Downmodulation of Plasmacytoid Dendritic Cell Functions by Vitamin D3 Analogue Calcipotriol","volume":"84","author":"Suzuki","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_19","first-page":"e129","article-title":"The Biological Rationale for Use of Vitamin d Analogs in Combination with Corticosteroids for the Topical Treatment of Plaque Psoriasis","volume":"12","author":"Segaert","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_20","first-page":"E79","article-title":"Effects of Topical Application of Betamethasone on Imiquimod-Induced Psoriasis-like Skin Inflammation in Mice","volume":"62","author":"Mori","year":"2016","journal-title":"Kobe J. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bugaut, H., and Aractingi, S. (2021). Major Role of the IL17\/23 Axis in Psoriasis Supports the Development of New Targeted Therapies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.621956"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e123390","DOI":"10.1172\/jci.insight.123390","article-title":"Disrupting the IL-36 and IL-23\/IL-17 Loop Underlies the Efficacy of Calcipotriol and Corticosteroid Therapy for Psoriasis","volume":"4","author":"Wei","year":"2019","journal-title":"JCI Insight"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1523-1747.2003.12626.x","article-title":"Epidermal Overexpression of Interleukin-19 and -20 mRNA in Psoriatic Skin Disappears after Short-Term Treatment with Cyclosporine a or Calcipotriol","volume":"121","author":"Steiniche","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.12659\/MSM.904850","article-title":"Effect of Calcipotriol on IFN-\u03b3-Induced Keratin 17 Expression in Immortalized Human Epidermal Keratinocyte Cells","volume":"23","author":"Zhang","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"ref_25","first-page":"628289","article-title":"The New Insight into the Role of Antimicrobial Proteins-Alarmins in the Immunopathogenesis of Psoriasis","volume":"2014","author":"Maj","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Peric, M., Koglin, S., Dombrowski, Y., Gross, K., Bradac, E., B\u00fcchau, A., Steinmeyer, A., Z\u00fcgel, U., Ruzicka, T., and Schauber, J. (2009). Vitamin D Analogs Differentially Control Antimicrobial Peptide\/\u201dalarmin\u201d Expression in Psoriasis. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006340"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2340\/00015555-1775","article-title":"Calcipotriol Increases hCAP18 mRNA Expression but Inhibits Extracellular LL37 Peptide Production in IL-17\/IL-22-Stimulated Normal Human Epidermal Keratinocytes","volume":"94","author":"Sakabe","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/1346-8138.16152","article-title":"Calcipotriol Induces the Production of CTACK\/CCL27, One of the Potential Suppressive Factors in Psoriasis Inflammation","volume":"48","author":"Karakawa","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/jid.2011.486","article-title":"Vitamin D Analog Calcipotriol Suppresses the Th17 Cytokine-Induced Proinflammatory S100 \u201cAlarmins\u201d Psoriasin (S100A7) and Koebnerisin (S100A15) in Psoriasis","volume":"132","author":"Hegyi","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2133.2006.07561.x","article-title":"A Double-Blind, Randomized Quantitative Comparison of Calcitriol Ointment and Calcipotriol Ointment on Epidermal Cell Populations, Proliferation and Differentiation","volume":"156","author":"Vissers","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11095-007-9388-z","article-title":"Calcipotriol Affects Keratinocyte Proliferation by Decreasing Expression of Early Growth Response-1 and Polo-like Kinase-2","volume":"25","author":"Kristl","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0923-1811(02)00136-6","article-title":"Similarly Potent Action of 1,25-Dihydroxyvitamin D3 and Its Analogues, Tacalcitol, Calcipotriol, and Maxacalcitol on Normal Human Keratinocyte Proliferation and Differentiation","volume":"31","author":"Takahashi","year":"2003","journal-title":"J. Dermatol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-4632.2007.03099.x","article-title":"Apoptosis, P53 and Bcl-2 Expression in Response to Topical Calcipotriol Therapy for Psoriasis","volume":"46","author":"Barakat","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1111\/j.1365-2230.2009.03518.x","article-title":"Calcipotriol Induces Apoptosis in Psoriatic Keratinocytes","volume":"34","author":"Tiberio","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/00015550410025930","article-title":"A Left\/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: The Effect on Keratinocyte Subpopulations","volume":"84","author":"Franssen","year":"2004","journal-title":"Acta Derm. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1684\/ejd.2022.4230","article-title":"Calcipotriol Inhibits Psoriasis-like Angiogenic Features in K14-VEGF Transgenic Mice","volume":"32","author":"Cao","year":"2022","journal-title":"Eur. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1039\/D1NR06001E","article-title":"Hydrogel-Mediated Topical Delivery of Steroids Can Effectively Alleviate Psoriasis via Attenuating the Autoimmune Responses","volume":"14","author":"Rana","year":"2022","journal-title":"Nanoscale"},{"key":"ref_38","first-page":"311","article-title":"Novel Quantitative Immunofluorescent Technique Reveals Improvements in Epidermal Cell Populations after Mild Treatment of Psoriasis","volume":"85","author":"Hagenberg","year":"2005","journal-title":"Acta Derm. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1468-3083.2006.01508.x","article-title":"The Effects of Calcipotriol and Methylprednisolone Aseponate on Bcl-2, P53 and Ki-67 Expression in Psoriasis","volume":"20","author":"Erdem","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2230.2009.03298.x","article-title":"Response of Cutaneous Microcirculation to Treatment with Mometasone Furoate in Patients with Psoriasis","volume":"34","author":"Stinco","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jdermsci.2015.12.009","article-title":"Calcipotriol and Betamethasone Dipropionate Exert Additive Inhibitory Effects on the Cytokine Expression of Inflammatory Dendritic Cell-Th17 Cell Axis in Psoriasis","volume":"81","author":"Lovato","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaci.2016.03.048","article-title":"Topical Application of a Vitamin D3 Analogue and Corticosteroid to Psoriasis Plaques Decreases Skin Infiltration of TH17 Cells and Their Ex Vivo Expansion","volume":"138","author":"Fujiyama","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjd.16336","article-title":"Differential Effects of Phototherapy, Adalimumab and Betamethasone-Calcipotriol on Effector and Regulatory T Cells in Psoriasis","volume":"179","author":"Kotb","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_44","first-page":"e33","article-title":"Changes in Interleukin-17A, Macrophage-Derived Chemokine and Adiponectin Following Treatment of Psoriasis with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam: Results from the PSO-ABLE Study","volume":"178","author":"Kaldate","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2340\/00015555-2579","article-title":"Clinical Efficiency of Topical Calcipotriol\/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNF\u03b1\u2013IL-23\u2013IL-17 Axis","volume":"97","author":"Kubin","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16322","DOI":"10.1038\/s41598-019-52892-1","article-title":"Calcipotriol and Betamethasone Dipropionate Synergistically Enhances the Balance between Regulatory and Proinflammatory T Cells in a Murine Psoriasis Model","volume":"9","author":"Satake","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13555-020-00482-9","article-title":"Calcipotriol\/Betamethasone Dipropionate Foam Inhibits Th17 Cytokine Secretion and Improves Epidermal Barrier Markers in a Human Th17 Skin Inflammation Model","volume":"11","author":"Lovato","year":"2021","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/1346-8138.15155","article-title":"Calcipotriol and Betamethasone Dipropionate Exhibit Different Immunomodulatory Effects on Imiquimod-induced Murine Psoriasiform Dermatitis","volume":"47","author":"Takeoka","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/1346-8138.13679","article-title":"Vitamin D3 Derivatives, Alone or in Combination with Glucocorticoids, Suppress Streptococcal Pyrogenic Enterotoxin A-Stimulated Proliferation of Peripheral Blood Mononuclear Cells in Patients with Psoriasis","volume":"44","author":"Usui","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09546630903214175","article-title":"Treatment of Plaque Psoriasis with the Two-Compound Product Calcipotriol\/Betamethasone Dipropionate versus Both Monotherapies: An Immunohistochemical Study","volume":"21","author":"Pasch","year":"2010","journal-title":"J. Dermatol. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000051730","article-title":"Treatment of Psoriasis with a New Combination of Calcipotriol and Betamethasone Dipropionate: A Flow Cytometric Study","volume":"203","year":"2001","journal-title":"Dermatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1479-5876-7-107","article-title":"Comparison of the Effects of Vitamin D Products in a Psoriasis Plaque Test and a Murine Psoriasis Xenograft Model","volume":"7","author":"Kvist","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.0906-6705.2004.00151.x","article-title":"The Effect of the Combination of Calcipotriol and Betamethasone Dipropionate versus Both Monotherapies on Epidermal Proliferation, Keratinization and T-Cell Subsets in Chronic Plaque Psoriasis","volume":"13","author":"Vissers","year":"2004","journal-title":"Exp. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1002\/hsr2.597","article-title":"Efficacy of Calcipotriol plus Betamethasone Dipropionate Foam on Psoriatic Skin Lesions beyond Human Eyes: An Observational Study","volume":"5","author":"Anna","year":"2022","journal-title":"Health Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00403-014-1485-3","article-title":"Calcipotriol Counteracts Betamethasone-Induced Decrease in Extracellular Matrix Components Related to Skin Atrophy","volume":"306","author":"Norsgaard","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_56","first-page":"747","article-title":"A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene\/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion","volume":"16","author":"Hashim","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0846.2008.00336.x","article-title":"Microcirculatory Modifications of Psoriatic Lesions during Topical Therapy","volume":"15","author":"Rosina","year":"2009","journal-title":"Skin Res. Technol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/srt.12198","article-title":"Clearing of Psoriasis Documented by Laser Doppler Perfusion Imaging Contrasts Remaining Elevation of Dermal Expression Levels of CD31","volume":"21","author":"Hendriks","year":"2015","journal-title":"Skin Res. Technol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/postgradmedj-2020-138150","article-title":"Shear Wave Elastography and Microvascular Ultrasound in Response Evaluation to Calcipotriol+betamethasone Foam in Plaque Psoriasis","volume":"97","author":"Guazzaroni","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jdv.16559","article-title":"Non-Invasive Clinical and Microscopic Evaluation of the Response to Treatment with Clobetasol Cream vs. Calcipotriol\/Betamethasone Dipropionate Foam in Mild to Moderate Plaque Psoriasis: An Investigator-Initiated, Phase IV, Unicentric, Open, Randomized Clinical Trial","volume":"35","author":"Alejo","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/00015550252948194","article-title":"A New Calcipotriol\/Betamethasone Formulation with Rapid Onset of Action Was Superior to Monotherapy with Betamethasone Dipropionate or Calcipotriol in Psoriasis Vulgaris","volume":"82","author":"Douglas","year":"2002","journal-title":"Acta Derm. Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000066440","article-title":"A New Calcipotriol\/Betamethasone Dipropionate Formulation (Daivobet) Is an Effective Once-Daily Treatment for Psoriasis Vulgaris","volume":"205","author":"Kaufmann","year":"2002","journal-title":"Dermatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mjd.2003.130","article-title":"Early Onset of Action and Efficacy of a Combination of Calcipotriene and Betamethasone Dipropionate in the Treatment of Psoriasis","volume":"48","author":"Papp","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5455\/njppp.2017.7.0721302082016","article-title":"Comparison of Efficacy of Calcipotriol and Betamethasone Combination with Betamethasone Alone in Plaque Psoriasis","volume":"7","author":"Singh","year":"2017","journal-title":"Natl. J. Physiol. Pharm. Pharmacol."},{"key":"ref_65","first-page":"AB124","article-title":"Results from a Randomized Study Comparing Clobetasol Propionate 0.05% Spray to Calcipotriene 0.005%, Betamethasone Dipropionate 0.064% Ointment for the Treatment of Plaque Psoriasis","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","first-page":"52","article-title":"Comparing Clobetasol Propionate 0.05% Spray to Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Ointment for the Treatment of Moderate to Severe Plaque Psoriasis","volume":"8","author":"Menter","year":"2009","journal-title":"J. Drugs Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jdv.12270","article-title":"Betamethasone Valerate Dressing Is Non-Inferior to Calcipotriol-Betamethasone Dipropionate Ointment in the Treatment of Patients with Mild-to-Moderate Chronic Plaque Psoriasis: Results of a Randomized Assessor-Blinded Multicentre Trial","volume":"28","author":"Ortonne","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_68","first-page":"112","article-title":"Calcipotriol\/Betamethasone Ointment and Dexamethasone Cream in the Treatment of Stable Psoriasis Vulgaris: A Self-Controlled, Parallel Group Study","volume":"43","author":"Sun","year":"2014","journal-title":"J. Clin. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2008.04.027","article-title":"A New Scalp Formulation of Calcipotriene plus Betamethasone Compared with Its Active Ingredients and the Vehicle in the Treatment of Scalp Psoriasis: A Randomized, Double-Blind, Controlled Trial","volume":"59","author":"Jemec","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000130425","article-title":"Calcipotriol plus Betamethasone Dipropionate Scalp Formulation Is Effective and Well Tolerated in the Treatment of Scalp Psoriasis: A Phase II Study","volume":"217","author":"Buckley","year":"2008","journal-title":"Dermatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2008.08927.x","article-title":"A New Scalp Formulation of Calcipotriol plus Betamethasone Dipropionate Compared with Each of Its Active Ingredients in the Same Vehicle for the Treatment of Scalp Psoriasis: A Randomized, Double-Blind, Controlled Trial","volume":"160","author":"Hoffmann","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1684\/ejd.2010.0948","article-title":"Calcipotriol plus Betamethasone Dipropionate Gel Compared with Its Active Components in the Same Vehicle and the Vehicle Alone in the Treatment of Psoriasis Vulgaris: A Randomised, Parallel Group, Double-Blind, Exploratory Study","volume":"20","author":"Fleming","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"ref_73","first-page":"92","article-title":"Calcipotriene plus Betamethasone Dipropionate Topical Suspension for the Treatment of Mild to Moderate Psoriasis Vulgaris on the Body: A Randomized, Double-Blind, Vehicle-Controlled Trial","volume":"12","author":"Menter","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_74","first-page":"34","article-title":"Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) Is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-Blind, Multicenter, Three-Arm, Phase 2 Study","volume":"9","author":"Lebwohl","year":"2016","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"AB222","DOI":"10.1016\/j.jaad.2015.02.901","article-title":"A Novel Aerosol Foam Formulation of Calcipotriene (Cal) 0.005% plus Betamethasone Dipropionate (BD) 0.064% Is More Efficacious than Cal and BD Foam Alone in Treating Psoriasis Vulgaris: A Randomized, Double-Blind, Multicenter, Three-Arm, Phase II Study","volume":"72","author":"Lebwohl","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_76","first-page":"12","article-title":"Efficacy of Fixed-Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study","volume":"13","author":"Patel","year":"2020","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"AB78","DOI":"10.1016\/j.jaad.2019.06.307","article-title":"Improvements in Efficacy and Lesion Quality in Scalp Plaque Psoriasis with Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal\/BD) Foam Treatment","volume":"81","author":"Patel","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40261-015-0269-7","article-title":"Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris","volume":"35","author":"Olesen","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40261-016-0489-5","article-title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis","volume":"37","author":"Rosen","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaad.2013.06.027","article-title":"Topical Treatments for Chronic Plaque Psoriasis: An Abridged Cochrane Systematic Review","volume":"69","author":"Mason","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","first-page":"CD009687","article-title":"Topical Treatments for Scalp Psoriasis","volume":"2","author":"Schlager","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_82","first-page":"1","article-title":"Once Daily Application of a Combination of Calcipotriol and Betamethasone Dipropionate (Dovobet, Daivobet) for the Treatment of Psoriasis","volume":"8","author":"Lui","year":"2003","journal-title":"Skin Ther. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-4632.2006.02939.x","article-title":"Retrospective Assessment of PASI 50 and PASI 75 Attainment with a Calcipotriol\/Betamethasone Dipropionate Ointment","volume":"45","author":"Anstey","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1468-3083.2005.01343.x","article-title":"Consistency of Data in Six Phase III Clinical Studies of a Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Ointment for the Treatment of Psoriasis","volume":"20","author":"Kragballe","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1185\/03007995.2010.541005","article-title":"Mixed Treatment Comparison of a Two-Compound Formulation (TCF) Product Containing Calcipotriol and Betamethasone Dipropionate with Other Topical Treatments in Psoriasis Vulgaris","volume":"27","author":"Ryttov","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/09546634.2015.1093590","article-title":"Topical Treatment for Scalp Psoriasis: Comparison of Patient Preference, Quality of Life and Efficacy for Non-Alcoholic Mometasone Emulsion versus Calcipotriol\/Betamethasone Gel in Daily Clinical Practice","volume":"27","author":"Gual","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1468-3083.2010.03682.x","article-title":"Significant One Week Efficacy of a Calcipotriol plus Betamethasone Dipropionate Scalp Formulation","volume":"25","author":"Jemec","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007995.2010.541022","article-title":"The Effectiveness of Two-Compound Formulation Calcipotriol and Betamethasone Dipropionate Gel in the Treatment of Moderately Severe Scalp Psoriasis: A Systematic Review of Direct and Indirect Evidence","volume":"27","author":"Bottomley","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_89","first-page":"951","article-title":"Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies","volume":"15","author":"Lebwohl","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_90","unstructured":"Papp, K., and Melgaard, A. (2007). Pooled Safety Data for a Calcipotriene\/Betamethasone Dipropionate Twocompound Product in the Treatment of Psoriasis Vulgaris, Mosby-Elsevier."},{"key":"ref_91","first-page":"75","article-title":"Association of Topical Psoriasis Treatment with Subsequent Disease Worsening or Secondary Care Referral: Analysis of a U.K. General Practice Database","volume":"173","author":"Zokaie","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.12788\/j.sder.2016.006","article-title":"Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence","volume":"35","year":"2016","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/ijd.ijd_422_23","article-title":"Topical Therapy in Psoriasis","volume":"68","author":"Ahmed","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1468-3083.2012.04523.x","article-title":"Topical Corticosteroids in Plaque Psoriasis: A Systematic Review of Risk of Adrenal Axis Suppression and Skin Atrophy","volume":"26","author":"Castela","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jdv.12444","article-title":"Pooled Safety Analysis of Calcipotriol plus Betamethasone Dipropionate Gel for the Treatment of Psoriasis on the Body and Scalp","volume":"28","author":"Kragballe","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_96","first-page":"AB131","article-title":"Pooled Safety Data of a Calcipotriene\/Betamethasone Dipropionate Two-Compound Scalp Formulation in the Treatment of Scalp Psoriasis","volume":"62","author":"Lowson","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_97","first-page":"119","article-title":"Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies","volume":"15","author":"Menter","year":"2017","journal-title":"Skinmed"},{"key":"ref_98","first-page":"969","article-title":"Short- and Long-Term Safety Assessment of a Two-Compound Ointment Containing Calcipotriene\/Betamethasone Dipropionate (Taclonex\/Daivobet\/Dovobet Ointment): Hypothalamic-Pituitary-Adrenal Axis Function in Patients with Psoriasis Vulgaris","volume":"9","author":"Fleming","year":"2010","journal-title":"J. Drugs Dermatol."},{"key":"ref_99","first-page":"882","article-title":"Effect of Calcipotriene plus Betamethasone Dipropionate Topical Suspension on the Hypothalamic-Pituitary-Adrenal Axis and Calcium Homeostasis in Subjects with Extensive Psoriasis Vulgaris: An Open, Non-Controlled, 8-Week Trial","volume":"12","author":"Silver","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jdv.17734","article-title":"A Pooled Analysis of Randomized, Controlled, Phase 3 Trials Investigating the Efficacy and Safety of a Novel, Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream for the Topical Treatment of Plaque Psoriasis","volume":"36","author":"Pinter","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s13555-023-01003-0","article-title":"Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review","volume":"13","author":"Torres","year":"2023","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/09546634.2015.1083935","article-title":"Superior Efficacy of Calcipotriene and Betamethasone Dipropionate Aerosol Foam versus Ointment in Patients with Psoriasis Vulgaris\u2014A Randomized Phase II Study","volume":"27","author":"Koo","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_103","unstructured":"Paul, C., Stein Gold, L., and Warren, R.B. (2015, January 7\u201311). Superior Efficacy of the Fixed Combination Calcipotriol plus Betamethasone Dipropionate Aerosol Foam versus Gel, in Patients with Psoriasis Vulgaris\u2014The Phase III PSO-ABLE Study. Proceedings of the 24th Congress of the European Academy of Dermatology and Venereology, Copenhagen, Denmark. Abst COP15-1087."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1684\/ejd.2018.3302","article-title":"Greater Improvement in Quality of Life Outcomes in Patients Using Fixed-Combination Calcipotriol plus Betamethasone Dipropionate Aerosol Foam versus Gel: Results from the PSO-ABLE Study","volume":"28","author":"Griffiths","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13555-016-0125-6","article-title":"Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients","volume":"6","author":"Lind","year":"2016","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/jdv.14515","article-title":"Patients with Psoriasis Have Different Preferences for Topical Therapy, Highlighting the Importance of Individualized Treatment Approaches: Randomized Phase IIIb PSO-INSIGHTFUL Study","volume":"31","author":"Hong","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Rudnicka, L., Olszewska, M., Goldust, M., Wa\u015bkiel-Burnat, A., Warszawik-Hendzel, O., Doro\u017cy\u0144ski, P., Tur\u0142o, J., and Rakowska, A. (2021). Efficacy and Safety of Different Formulations of Calcipotriol\/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235589"},{"key":"ref_108","first-page":"242","article-title":"Pooled Analysis Demonstrating Superior Patient-Reported Psoriasis Treatment Outcomes for Calcipotriene\/ Betamethasone Dipropionate Cream Versus Suspension\/Gel","volume":"21","author":"Armstrong","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_109","unstructured":"Phillippo, D., Ades, T., Dias, S., Palmer, S., Abrams, K.R., and Welton, N. (2024, April 04). NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE. Report by the Decision Support Unit. Available online: http:\/\/www.nicedsu.org.uk."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1080\/09546634.2022.2116924","article-title":"An Anchored Matching-Adjusted Indirect Comparison of Fixed-Dose Combination Calcipotriol and Betamethasone Dipropionate (Cal\/BDP) Cream versus Cal\/BDP Foam for the Treatment of Psoriasis","volume":"33","author":"Bewley","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1080\/09546634.2022.2095330","article-title":"Matching-Adjusted Indirect Comparison of Efficacy Outcomes in Trials of Calcipotriol plus Betamethasone Dipropionate Foam and Cream Formulations for the Treatment of Plaque Psoriasis","volume":"33","author":"Papp","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2357618","DOI":"10.1080\/09546634.2024.2357618","article-title":"Real-World Use, Perception, Satisfaction, and Adherence of Calcipotriol and Betamethasone Dipropionate PAD-Cream in Patients with Plaque Psoriasis in Spain and Germany: Results from a Cross-Sectional, Online Survey","volume":"35","author":"Kurzen","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_113","unstructured":"Kircik, L.H. (2023, January 11\u201314). Patient Preference for Cream or Foam Fixed-Dose Combination of Calcipotriene (a Vitamin D Analog) and Betamethasone Dipropionate: Results of a Split Body and Scalp Study in Patients with Mild to Moderate Plaque Psoriasis. Proceedings of the 32nd EADV Congress, Berlin, Germany."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the Pathogenesis of Psoriasis: From Keratinocyte Perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13555-017-0196-z","article-title":"Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy","volume":"7","author":"Segaert","year":"2017","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Anyfanti, P., Margouta, A., Goulas, K., Gavriilaki, M., Lazaridou, E., Patsatsi, A., and Gkaliagkousi, E. (2022). Endothelial Dysfunction in Psoriasis: An Updated Review. Front. Med., 9.","DOI":"10.3389\/fmed.2022.864185"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/2229-5178.209622","article-title":"Topical Therapies in Psoriasis","volume":"8","author":"Torsekar","year":"2017","journal-title":"Indian Dermatol. Online J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s13555-022-00794-y","article-title":"Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application","volume":"12","author":"Praestegaard","year":"2022","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"561018","DOI":"10.1155\/2012\/561018","article-title":"Mechanisms of Action of Topical Corticosteroids in Psoriasis","volume":"2012","author":"Uva","year":"2012","journal-title":"Int. J. Endocrinol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04060.x","article-title":"Maximizing Patient Adherence for Optimal Outcomes in Psoriasis","volume":"25","author":"Bewley","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/cobi.12541","article-title":"Making Literature Reviews More Reliable through Application of Lessons from Systematic Reviews","volume":"29","author":"Haddaway","year":"2015","journal-title":"Conserv. Biol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:15Z","timestamp":1760110035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":121,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13154484"],"URL":"https:\/\/doi.org\/10.3390\/jcm13154484","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}